Yuehchukene, a bis-indole alkaloid, and cyclophosphamide are active in breast cancer in vitro

Chemotherapy

Volumn 46, Issue 1, 2000, Pages 62-68

  Leung, Thomas W T ^a,c   Cheng, G ^a   Chui, C H ^a   Ho, S K W ^a   Lau, F Y ^a   Tjong, J K J ^a   Poon, T C C ^a   Tang, J C O ^b   Tse, W C P ^a   Cheng, K F ^a   Kong, Y C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Breast cancer; Estrogen; Yuehchukene

Indexed keywords

CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN RECEPTOR; YUEHCHUKENE;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0033987205     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007257     Document Type: Article

References (21)

1. Main Causes of Death from Cancer in Hong Kong, 1982-1992. Hong Kong Department of Health Annual Report (1991/1992). Hong Kong, Department of Health, 1993.
2. King WWK, Wang TP, Lau JTF, Chung SSC, Johnson PJ, Li ACK: Analysis of 346 Chinese patients with breast cancer. Hong Kong Med J 1996;2:72-79.
3. Early Brest Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:1-15, 71-85.
4. Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC: Investigation of the mechanism of tamoxifen-stimulated breast tumor growth using non-isomerizable analogs of tamoxifen and metabolites. J Natl Cancer Inst 1993;85:806-812.
5. Kong YC, Ng KH, Wat KH, Wong A, Saxena IF, Cheng KF, But PPH, Chang HT: Yuehchukene - a novel anti-implantation indole alkaloid from Murraya paniculata. Planta Med 1985;51:304-307.
6. Chan WL, Ho DD, Lu CP, Wat KH, Kong YC, Cheng KF, Wong TT, Chan TY: Structur function relationship of Yuehchukene. I. Anti-implantation and estrogenic activities of substituted yuehchukene derivatives. Eur J Med Chem 1991;26: 387-394.
7. Cheng KF, Wong TT, Chang KP, Kong YC: Structure-function relationship of yuehchukene. II. The effect of C-6 indole rotation in anti-implantation activity. Eur J Med Chem 1992;27:121-130.
8. Ng PC, Ho DD, Ng KH, Kong YC, Cheng KF, Stone G: Mixed estrogenic and anti-estrogenic activities of yuehchukene - a bis-indole alkaloid. Eur J Pharmacol 1994;264:1-12.
9. The International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node positive postmenopausal breast cancer patients. J Clin Oncol 1997;15:1385-1394.
10. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87: 645-651.
11. Buzdar A, Jonat W, Howell A, Jones S, Blomqvist C, Vogen CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-2005.
12. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-750.
13. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Cafbone PP, Demets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
14. Love RR, Newcomb PA, Wiebe DA: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node negative breast cancer. J Natl Cancer Inst 1990;82:1327-1332.
15. Chen L, Waxman DJ: Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995;55:581-589.
16. Christou M, Savas U, Spink DC, Gierthy JF, Jefcoate CR: Co-expression of human CYP1A1 and a human analog of cytochrome P450-EF in response to 2,37,8-tetrachloro-dibenzo-p-dioxin in the human mammary carcinoma-derived MCF-7 cells. Carcinogenesis 1994;15:725-732.
17. Chen L, Waxman DJ, Chen D, Kufe DW: Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996;56:1331-1340.
18. Busse D, Busch FW, Schweizer E, Bohnenstengel F, Eichelbaum M, Fischer P, Schumacher K, Aulitzky WE, Kroemer HK: Fractionated administration of high-dose cyclophosphamide: Influence on dose-dependent changes in pharmacokinetics and metabolism. Cancer Chemother Pharmacol 1999;43:263-268.
19. Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E: Genetic alterations of c-myc, c-erbB-2, and c-H-ras proto-oncogenes and clinical associations in human breast carcinomas. Cancer Res 1989;49:6675-6679.
20. Kwong YL: Gene therapy - perspectives and promises. Hong Kong Med J 1997;3:163-172.
21. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, Callahan R: Genetic alteration of the c-myc proto-oncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 1986;83: 4834-4838.